| European Case Law Identifier: | ECLI:EP:BA:1994:T041293.19941121 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Date of decision: | 21 November 1994 | ||||||||
| Case number: | T 0412/93 | ||||||||
| Application number: | 84308654.7 | ||||||||
| IPC class: | C12N 15/00 | ||||||||
| Language of proceedings: | EN | ||||||||
| Distribution: | B | ||||||||
| Download and more information: |
|
||||||||
| Title of application: | Production of erythropoietin | ||||||||
| Applicant name: | Kirin-Amgen, Inc. | ||||||||
| Opponent name: | Genzyme Corporation Elanex Pharmaceuticals Inc. Merckle GmbH Chem.-pharm. Fabrik Boehringer Mannheim GmbH Patentabteilung Behringwerke Aktiengesellschaft Akzo Pharma B.V. |
||||||||
| Board: | 3.3.04 | ||||||||
| Headnote: | - | ||||||||
| Relevant legal provisions: | |||||||||
| Keywords: | Circumstances where novelty of product by process features can be acknowledged Sufficiency of disclosure of a dependent claim - no Deposit not required by Rule 28 and Article 83 EPC to make something already possible easier; no best mode requirement under the EPC Inventive step - yes Novelty - product by process features |
||||||||
| Catchwords: |
- |
||||||||
| Cited decisions: |
|
||||||||
| Citing decisions: | |||||||||
Source: http://www.epo.org/law-practice/case-law-appeals/recent/t930412eu1.html
Date retrieved: 17 May 2021